Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADMA BiologicsADMA -5.53%64 Days Sales Outstanding is 100.53 as of Jun. 2026, which is 120% above its 10-year median of 45.74. GuruFocus rates ADMA with a GF Score™ of 64/100 and a GF Value™ of $18.36 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, ADMA Biologics ranks worse than 68.49% on this metric.
ADMA Biologics's average Accounts Receivable for the
three
months ended in Jun. 2026 was $137.0 Mil. ADMA Biologics's Revenue for the
three
months ended in Jun. 2026 was $124.4 Mil.
Hence, ADMA Biologics's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 100.53.
The historical rank and industry rank for ADMA Biologics's Days Sales Outstanding or its related term are showing as below:
ADMA'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 30.23 Med: 45.74 Max: 96.89
Current: 96.89
During the past 13 years, ADMA Biologics's highest Days Sales Outstanding was 96.89. The lowest was 30.23. And the median was 45.74.
ADMA's Days Sales Outstanding is ranked worse than 68.49% of 841
companies
in the Biotechnology industry
Industry Median: 68.98
vs ADMA: 96.89
ADMA Biologics's Days Sales Outstanding
increased
from Jun. 2025 (78.22) to Jun. 2026 (100.53).
Warning Sign:
If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.
ADMA Biologics (NAS:ADMA) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
ADMA Biologics Days Sales Outstanding Related Terms
ADMA Biologics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for ADMA Biologics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADMA vs VCEL, COAG, KLRA: Days Sales Outstanding Comparison
For the Biotechnology subindustry, ADMA Biologics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 100.53 mean?
ADMA Biologics (ADMA) has a Days Sales Outstanding of 100.53 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ADMA Biologics and its competitors. This is 120% above median its historical median of 45.74. Over the past decade, ADMA Biologics' Days Sales Outstanding has ranged from 30.23 to 96.89. According to the industry distribution chart, ADMA Biologics ranks #576 out of 841 companies in the Biotechnology industry, placing it in the top 68.5%.
Is ADMA Biologics' Days Sales Outstanding too high?
ADMA Biologics' current Days Sales Outstanding of 100.53 is 120% above median its 10-year median of 45.74. Over the past 10 years, this metric has ranged from a low of 30.23 to a high of 96.89. The Biotechnology industry median Days Sales Outstanding is 68.98. ADMA Biologics' value of 100.53 is 45.7% above this industry median. Based on the distribution chart, ADMA Biologics ranks #576 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ADMA Biologics has a GF Score™ of 64/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ADMA Biologics' Days Sales Outstanding compare to VCEL and COAG?
According to the Biotechnology industry distribution chart, ADMA Biologics ranks #576 out of 841 companies for Days Sales Outstanding. This places ADMA Biologics in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. ADMA Biologics' value of 100.53 is 45.7% above this benchmark. Historically, ADMA Biologics' own Days Sales Outstanding has ranged from 30.23 to 96.89 over the past decade. While the company's 10-year median is 45.74 vs. the industry median of 68.98, ADMA Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADMA Biologics's current Days Sales Outstanding of 100.53 is 45.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on ADMA Biologics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADMA Biologics's current Days Sales Outstanding is 100.53, which is 120% above median its own 10-year median of 45.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADMA Biologics stock overvalued right now?
Based on GuruFocus' analysis, ADMA Biologics (ADMA) is currently considered Significantly Undervalued. The stock's GF Value™ is $18.36, compared to a current price of $8.64 — trading 53% below its estimated fair value. The current Days Sales Outstanding is 100.53, which is 120% above median its 10-year median of 45.74 and 45.7% above the Biotechnology industry median of 68.98. ADMA Biologics' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For ADMA Biologics (ADMA), the current Days Sales Outstanding is 100.53 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADMA Biologics (ADMA) Overvalued in 2026?
Based on GuruFocus' analysis, ADMA Biologics stock appears to be undervalued.
The current stock price of $8.64 is trading 53% below its estimated GF Value™ of $18.36.
GuruFocus considers ADMA Biologics to be Significantly Undervalued.
Key valuation signals for ADMA:
Days Sales Outstanding: 100.53 (120% above median its 10-year median of 45.74)
GF Value™: $18.36 vs. price of $8.64 (53% below fair value)
Industry Position: 45.7% above the Biotechnology median (#576 of 841)
No single metric tells the full story. See the ADMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.
64GF Score
Get the complete analysis for ADMA
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADMA has been successfully added to your 
